IPI-145 - Duvelisib | INK-1197

Based on 210 reference(s) in Google Scholar 8 10 210

Axon 4133

CAS [1201438-56-3]

MF C22H17ClN6O
MW 416.86

  • Purity: 99%
  • Optical purity: 99% e.e.
  • Soluble in DMSO
Recently added

IPI-145

Description

IPI-145 is an orally bioavailable PI3K/P110δ/γ isoform-specific inhibitor, with Ki values: P110δ (23 pM), P110γ (243 pM), p110α (25900 pM) and p110β (1564 pM). IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation. IPI-145 showed potent activity in collagen-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus rodent models.

Keywords: IPI-145 | Supplier | PI3K inhibitor | Duvelisib | INK-1197 | IPI145 | IPI 145 | INK1197 | INK 1197 | CT-IPI145 | CAS [1201438-56-3] | Phosphatidylinositol | PI3K | Inhibitor | Enzymes

PI3K p110α/γ isoform specific inhibitor

Chemical name

(S)-3-(1-(9H-Purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one

Source information

Sold in collaboration with Chemietek

Parent CAS No.

[1201438-56-3]

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...